Patents by Inventor Xanthe M. Lam
Xanthe M. Lam has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9283273Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.Type: GrantFiled: September 14, 2012Date of Patent: March 15, 2016Assignee: GENENTECH, INC.Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
-
Patent number: 9266961Abstract: The invention provides anti-PCSK9 antibodies, formulations, dosing regimens, and methods of using the same.Type: GrantFiled: June 14, 2013Date of Patent: February 23, 2016Assignee: Genentech, Inc.Inventors: Yan Wu, Cecilia Pui Chi Chiu, Daniel K. Kirchhofer, Andrew Peterson, Ganesh A. Kolumam, Monica Kong Beltran, Paul Moran, Wei Li, Xanthe M. Lam, Lin Luis, Ada Hui
-
Publication number: 20130224185Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.Type: ApplicationFiled: September 14, 2012Publication date: August 29, 2013Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
-
Publication number: 20110236383Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.Type: ApplicationFiled: June 8, 2011Publication date: September 29, 2011Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
-
Publication number: 20100330184Abstract: The invention provides injection vehicles suitable for administering particulate suspensions, such as polymer-based formulations, as well as associated pharmaceutical formulations, articles of manufacture, and kits. Other aspects of the invention included methods for producing and administering pharmaceutical formulations. The injection vehicles of the invention are superior to conventional injection vehicles in that they include a pseudoplastic composition that improves injectability, which facilitates delivery of the desired dose. The injection vehicles of the invention also allow the use of smaller-bore needles than are usually necessary to inject polymer-based formulations, reducing the pain associated with injection of such formulations.Type: ApplicationFiled: December 18, 2009Publication date: December 30, 2010Inventors: Jeffrey L. Cleland, Xanthe M. Lam, Franklin Okumu
-
Publication number: 20100158899Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.Type: ApplicationFiled: February 2, 2010Publication date: June 24, 2010Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
-
Patent number: 7682609Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.Type: GrantFiled: May 26, 2006Date of Patent: March 23, 2010Assignee: Genentech, Inc.Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
-
Patent number: 7651703Abstract: The invention provides injection vehicles suitable for administering particulate suspensions, such as polymer-based formulations, as well as associated pharmaceutical formulations, articles of manufacture, and kits. Other aspects of the invention included methods for producing and administering pharmaceutical formulations. The injection vehicles of the invention are superior to conventional injection vehicles in that they include a pseudoplastic composition that improves injectability, which facilitates delivery of the desired dose. The injection vehicles of the invention also allow the use of smaller-bore needles than are usually necessary to inject polymer-based formulations, reducing the pain associated with injection of such formulations.Type: GrantFiled: December 21, 2006Date of Patent: January 26, 2010Assignee: Genentech, Inc.Inventors: Jeffrey L. Cleland, Xanthe M. Lam, Franklin Okumu
-
Patent number: 7582311Abstract: The invention provides injection vehicles suitable for administering particulate suspensions, such as polymer-based formulations, as well as associated pharmaceutical formulations, articles of manufacture, and kits. Other aspects of the invention included methods for producing and administering pharmaceutical formulations. The injection vehicles of the invention are superior to conventional injection vehicles in that they include a pseudoplastic composition that improves injectability, which facilitates delivery of the desired dose. The injection vehicles of the invention also allow the use of smaller-bore needles than are usually necessary to inject polymer-based formulations, reducing the pain associated with injection of such formulations.Type: GrantFiled: October 13, 2000Date of Patent: September 1, 2009Assignee: Genentech, Inc.Inventors: Jeffrey L. Cleland, Xanthe M. Lam, Franklin Okumu
-
Patent number: 7163701Abstract: NGF microencapsulation compositions having controlled release characteristics, preferably with increased stability, for the NGF component, particularly human recombinant NGF (“rhNGF”) are provided that yield enhanced stability of NGF for use in promoting nerve cell growth, repair, survival, differentiation, maturation or function. Methods for making and using such compositions are also provided.Type: GrantFiled: May 20, 2003Date of Patent: January 16, 2007Assignee: Genentech, Inc.Inventors: Jeffrey L. Cleland, Xanthe M. Lam, Eileen T. Duenas
-
Patent number: 7060268Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.Type: GrantFiled: May 2, 2003Date of Patent: June 13, 2006Assignee: Genentech, Inc.Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
-
Patent number: 6991790Abstract: A stable aqueous pharmaceutical formulation comprising a therapeutically effective amount of antibody not subjected to prior lyophilization, a buffer maintaining the pH in the range from about 4.5 to about 6.0, a surfactant and a polyol is described, along with uses for such a formulation.Type: GrantFiled: November 28, 2000Date of Patent: January 31, 2006Assignee: Genentech, Inc.Inventors: Xanthe M. Lam, James Q. Oeswein, Boonsri Ongpipattanakul, Zehra Shahrokh, Sharon X. Wang, Robert P. Weissburg, Rita L. Wong
-
Patent number: 6964947Abstract: Formulations are provided comprising NGF and acetate-containing buffer from pH 5 to 6 that provide enhanced stability of NGF for use in promoting nerve cell growth, repair, survival, differentiation, maturation or function.Type: GrantFiled: July 18, 2000Date of Patent: November 15, 2005Assignee: Genentech, Inc.Inventors: Linda R. De Young, Xanthe M. Lam, Tue H. Nguyen, Michael F. Powell
-
Patent number: 6821515Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.Type: GrantFiled: August 25, 2000Date of Patent: November 23, 2004Assignee: Genentech, Inc.Inventors: Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Janet Yu-Feng Yang
-
Publication number: 20040097417Abstract: Formulations are provided comprising NGF and acetate-containing buffer from pH 5 to 6 that provide enhanced stability of NGF for use in promoting nerve cell growth, repair, survival, differentiation, maturation or function.Type: ApplicationFiled: November 6, 2003Publication date: May 20, 2004Inventors: Linda R. DeYoung, Xanthe M. Lam, Tue H. Nguyen, Michael F. Powell
-
Patent number: 6685940Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.Type: GrantFiled: March 14, 2001Date of Patent: February 3, 2004Assignee: Genentech, Inc.Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
-
Patent number: 6663899Abstract: NGF microencapsulation compositions having controlled release characteristics, preferably with increased stability, for the NGF component, particularly human recombinant NGF (“rhNGF”) are provided that yield enhanced stability of NGF for use in promoting nerve cell growth, repair, survival, differentiation, maturation or function. Methods for making and using such compositions are also provided.Type: GrantFiled: June 11, 1998Date of Patent: December 16, 2003Assignee: Genentech, Inc.Inventors: Jeffrey L. Cleland, Xanthe M. Lam, Eileen T. Duenas
-
Publication number: 20030202972Abstract: A stable lyophilized protein formulation is described which can be reconstituted with a suitable diluent to generate a high protein concentration reconstituted formulation which is suitable for subcutaneous administration. For example, anti-IgE and anti-HER2 antibody formulations have been prepared by lyophilizing these antibodies in the presence of a lyoprotectant. The lyophilized mixture thus formed is reconstituted to a high protein concentration without apparent loss of stability of the protein.Type: ApplicationFiled: May 2, 2003Publication date: October 30, 2003Applicant: Genentech, Inc.Inventors: James Andya, Jeffrey L. Cleland, Chung C. Hsu, Xanthe M. Lam, David E. Overcashier, Steven J. Shire, Janet Yu-Feng Yang, Sylvia Sau-Yan Wu
-
Publication number: 20030203040Abstract: NGF microencapsulation compositions having controlled release characteristics, preferably with increased stability, for the NGF component, particularly human recombinant NGF (“rhNGF”) are provided that yield enhanced stability of NGF for use in promoting nerve cell growth, repair, survival, differentiation, maturation or function. Methods for making and using such compositions are also provided.Type: ApplicationFiled: May 20, 2003Publication date: October 30, 2003Inventors: Jeffrey L. Cleland, Xanthe M. Lam, Eileen T. Duenas
-
Publication number: 20020004481Abstract: NGF microencapsulation compositions having controlled release characteristics, preferably with increased stability, for the NGF component, particularly human recombinant NGF (“rhNGF”) are provided that yield enhanced stability of NGF for use in promoting nerve cell growth, repair, survival, differentiation, maturation or function. Methods for making and using such compositions are also provided.Type: ApplicationFiled: June 11, 1998Publication date: January 10, 2002Inventors: JEFFREY L. CLELAND, XANTHE M. LAM, EILEEN T. DUENAS